(S)-isobutyl 2-amino-3-phenylpropanoate hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-isobutyl 2-amino-3-phenylpropanoate hydrochloride
• 英文别名: L-phenylalanine isobutyl ester hydrochloride；2-methylpropyl (2S)-2-amino-3-phenylpropanoate;hydrochloride
• 化学式: C₁₃H₁₉NO₂*ClH
• 分子量: 257.76
• InChiKey: UKMSDKKSWOLCJM-YDALLXLXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.18
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-isobutyl 2-amino-3-phenylpropanoate hydrochloride 、 N₆-cyclopropyl-2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine 在 (S)-isobutyl 2-amino-3-phenylpropanoate hydrochloride 作用下， 以50的产率得到化合物 T25466
  参考文献：
  名称：

  [EN] PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES
  [FR] PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES POUR TRAITER DES MALADIES VIRALES

  摘要：

  描述了公式（I）的化合物和组合物，用作抗增殖剂，特别是抗人乳头瘤病毒。

  公开号：

  WO2005066189A1
• 作为试剂：
  描述：

  (S)-isobutyl 2-amino-3-phenylpropanoate hydrochloride 、 N₆-cyclopropyl-2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine 在 (S)-isobutyl 2-amino-3-phenylpropanoate hydrochloride 作用下， 以50的产率得到化合物 T25466
  参考文献：
  名称：

  [EN] PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES
  [FR] PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES POUR TRAITER DES MALADIES VIRALES

  摘要：

  描述了公式（I）的化合物和组合物，用作抗增殖剂，特别是抗人乳头瘤病毒。

  公开号：

  WO2005066189A1

文献信息

• Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof
  申请人：Shibata Riri

  公开号：US20060046981A1

  公开（公告）日：2006-03-02

  Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-nonmelanoma carcinoma agents, wherein: Y 1A and Y 1B are independently Y 1 ; R X1 and R X2 are independently R X ; Y 1 is ═O, —O(R X ), ═S, —N(R X ), —N(O)(R X ), —N(OR X ), —N(O)(OR X ), or —N(N(R X )(R X )); R X is independently R 1 , R 2 , R 4 , W 3 , or a protecting group; R 1 is independently —H or alkyl of 1 to 18 carbon atoms; R 2 is independently R 3 or R 4 wherein each R 4 is independently substituted with 0 to 3 R 3 groups or taken together at a carbon atom, two R 2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R 3 groups; R 3 is R 3a , R 3b , R 3c or R 3d , provided that when R 3 is bound to a heteroatom, then R 3 is R 3c or R 3d ; R 3a is —H, —F, —Cl, —Br, —I, —CF 3 , —CN, N 3 , —NO 2 , or —OR 4 ; R 3b is ═O, —O(R 4 ), ═S, —N(R 4 ), —N(O)(R 4 ), —N(OR 4 ), —N(O)(OR 4 ), or —N(N(R 4 )(R 4 )); R 3c is —R 4 , —N(R 4 )(R 4 ), —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —S(O)(OR 4 ), —S(O) 2 (OR 4 ), —OC(R 3b )R 4 , —OC(R 3b )OR 4 , —OC(R 3b )(N(R 4 )(R 4 )), —SC(R 3b )R 4 , —SC(R 3b )OR 4 , —SC(R 3b )(N(R 4 )(R 4 )), —N(R 4 )C(R 3b )R 4 , —N(R 4 )C(R 3b )OR 4 , —N(R 4 )C(R 3b )(N(R 4 )(R 4 )), W 3 or —R 5 W 3 ; R 3d is —C(R 3b )R 4 , —C(R 3b )OR 4 , —C(R 3b )W 3 , —C(R 3b )OW 3 or —C(R 3b )(N(R 4 )(R 4 )); R 4 is —H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R 5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W 3 is W 4 or W 5 ; W 4 is R 6 , —C(R 3b )R 6 , —C(R 3b )W 5 , —SO M2 R 6 , or —SO M2 W 5 , wherein R 6 is R 4 wherein each R 4 is substituted with 0 to 3 R 3 groups; W 5 is carbocycle or heterocycle wherein W 5 is independently substituted with 0 to 3 R 2 groups; and M2 is 0, 1 or 2; and pharmaceutically acceptable salts thereof.

  描述了公式I的化合物和组合物，作为抗增殖剂，特别是抗非黑色素瘤癌剂，其中：Y1A和Y1B独立地为Y1；RX1和RX2独立地为RX；Y1为═O，—O（RX），═S，—N（RX），—N（O）（RX），—N（ORX），—N（O）（ORX）或—N（N（RX）（RX））；RX独立地为R1、R2、R4、W3或保护基；R1独立地为—H或1至18个碳原子的烷基；R2独立地为R3或R4，其中每个R4独立地用0至3个R3基取代或在碳原子上结合在一起，形成3至8个碳的环，该环可用0至3个R3基取代；R3为R3a、R3b、R3c或R3d，但当R3结合到杂原子时，R3为R3c或R3d；R3a为—H、—F、—Cl、—Br、—I、—CF3、—CN、N3、—NO2或—OR4；R3b为═O、—O（R4）、═S、—N（R4）、—N（O）（R4）、—N（OR4）、—N（O）（OR4）或—N（N（R4）（R4））；R3c为—R4、—N（R4）（R4）、—SR4、—S（O）R4、—S（O）2R4、—S（O）（OR4）、—S（O）2（OR4）、—OC（R3b）R4、—OC（R3b）OR4、—OC（R3b）（N（R4）（R4））、—SC（R3b）R4、—SC（R3b）OR4、—SC（R3b）（N（R4）（R4））、—N（R4）C（R3b）R4、—N（R4）C（R3b）OR4、—N（R4）C（R3b）（N（R4）（R4））、W3或—R5W3；R3d为—C（R3b）R4、—C（R3b）OR4、—C（R3b）W3、—C（R3b）OW3或—C（R3b）（N（R4）（R4））；R4为—H或1至18个碳原子的烷基、2至18个碳原子的烯基或2至18个碳原子的炔基；R5为1至18个碳原子的烷基、2至18个碳原子的烯基或2至18个碳原子的炔基；W3为W4或W5；W4为R6、—C（R3b）R6、—C（R3b）W5、—SOM2R6或—SOM2W5，其中R6为R4，其中每个R4用0至3个R3基取代；W5为碳环或杂环，其中W5独立地用0至3个R2基取代；M2为0、1或2；以及其药学上可接受的盐。
• Anti-proliferative compounds, compositions, and methods of use thereof
  申请人：Cheng Xiaoqin

  公开号：US20060030545A1

  公开（公告）日：2006-02-09

  Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y 1A and Y 1B are independently Y 1 ; R X1 is R X ; R X2 is alkenyl of 2 to 18 carbon atoms or alkynyl of 2 to 18 carbon atoms; Y 1 is ═O, —O(R X ), ═S, —N(R X ), —N(O)(R X ), —N(OR X ), —N(O)(OR X ), or —N(N(R X )(R X )); R X is independently R 1 , R 2 , R 4 , W 3 , or a protecting group; R 1 is independently —H or alkyl of 1 to 18 carbon atoms; R 2 is independently R 3 or R 4 wherein each R 4 is independently substituted with 0 to 3 R 3 groups or taken together at a carbon atom, two R 2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R 3 groups; R 3 is R 3a , R 3b , R 3c or R 3d , provided that when R 3 is bound to a heteroatom, then R 3 is R 3c or R 3d ; R 3a is —H, —F, —Cl, —Br, —I, —CF 3 , —CN, N 3 , —NO 2 , or —OR 4 ; R 3b is ═O, —O(R 4 ), ═S, —N(R 4 ), —N(O)(R 4 ), —N(OR 4 ), —N(O)(OR 4 ), or —N(N(R 4 )(R 4 )); R 3c is —R 4 , —N(R 4 )(R 4 ), —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —S(O)(OR 4 ), —S(O) 2 (OR 4 ), —OC(R 3b )R 4 , —OC(R 3b )OR 4 , —OC(R 3b )(N(R 4 )(R 4 )), —SC(R 3b )R 4 , —SC(R 3b )OR 4 , —SC(R 3b )(N(R 4 )(R 4 )), —N(R 4 )C(R 3b )R 4 , —N(R 4 )C(R 3b )OR 4 , —N(R 4 )C(R 3b )(N(R 4 )(R 4 )), W 3 or —R 5 W 3 ; R 3d is —C(R 3b )R 4 , —C(R 3b )OR 4 , —C(R 3b )W 3 , —C(R 3b )OW 3 or —C(R 3b )(N(R 4 )(R 4 )); R 4 is —H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R 5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W 3 is W 4 or W 5 ; W 4 is R 6 , —C(R 3b )R 6 , —C(R 3b )W 5 , —SO M2 R 6 , or —SO M2 W 5 , wherein R 6 is R 4 wherein each R 4 is substituted with 0 to 3 R 3 groups; W 5 is carbocycle or heterocycle wherein W 5 is independently substituted with 0 to 3 R 2 groups; and M2 is 0, 1 or 2; or pharmaceutically acceptable salts thereof.

  描述了公式I的化合物和组合物，可用作抗增殖剂，特别是抗HPV，其中：Y1A和Y1B分别为Y1；RX1为RX；RX2为2至18个碳原子的烯基或2至18个碳原子的炔基；Y1为═O，—O（RX），═S，—N（RX），—N（O）（RX），—N（ORX），—N（O）（ORX）或—N（N（RX）（RX））；RX独立地为R1、R2、R4、W3或保护基；R1独立地为—H或1至18个碳原子的烷基；R2独立地为R3或R4，其中每个R4独立地用0至3个R3基取代或在碳原子上结合在一起，两个R2基形成3至8个碳原子的环，该环可以用0至3个R3基取代；R3为R3a、R3b、R3c或R3d，但当R3结合到杂原子时，R3为R3c或R3d；R3a为—H、—F、—Cl、—Br、—I、—CF3、—CN、N3、—NO2或—OR4；R3b为═O、—O（R4）、═S、—N（R4）、—N（O）（R4）、—N（OR4）、—N（O）（OR4）或—N（N（R4）（R4））；R3c为—R4、—N（R4）（R4）、—SR4、—S（O）R4、—S（O）2R4、—S（O）（OR4）、—S（O）2（OR4）、—OC（R3b）R4、—OC（R3b）OR4、—OC（R3b）（N（R4）（R4））、—SC（R3b）R4、—SC（R3b）OR4、—SC（R3b）（N（R4）（R4））、—N（R4）C（R3b）R4、—N（R4）C（R3b）OR4、—N（R4）C（R3b）（N（R4）（R4））、W3或—R5W3；R3d为—C（R3b）R4、—C（R3b）OR4、—C（R3b）W3、—C（R3b）OW3或—C（R3b）（N（R4）（R4））；R4为—H，或1至18个碳原子的烷基、2至18个碳原子的烯基或2至18个碳原子的炔基；R5为1至18个碳原子的亚烷基、2至18个碳原子的烯基亚烷基或2至18个碳原子的炔基亚烷基；W3为W4或W5；W4为R6、—C（R3b）R6、—C（R3b）W5、—SOM2R6或—SOM2W5，其中R6为R4，其中每个R4用0至3个R3基取代；W5为碳环或杂环，其中W5独立地用0至3个R2基取代；M2为0、1或2；或其药学上可接受的盐。
• ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Cheng Xiaoqin

  公开号：US20090291922A1

  公开（公告）日：2009-11-26

  Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y 1A and Y 1B are independently Y 1 ; R X1 and R X2 are independently R X ; Y 1 is ═O, —O(R X ), ═S, —N(R X ), —N(O)(R X ), —N(OR X ), —N(O)(OR X ), or —N(N(R X )(R X )); R X is independently R 1 , R 2 , R 4 , W 3 , or a protecting group; R 1 is independently —H or alkyl of 1 to 18 carbon atoms; R 2 is independently R 3 or R 4 wherein each R 4 is independently substituted with 0 to 3 R 3 groups or taken together at a carbon atom, two R 2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R 3 groups; R 3 is R 3a , R 3b , R 3c or R 3d , provided that when R 3 is bound to a heteroatom, then R 3 is R 3c or R 3d ; R 3a is —H, —F, —Cl, —Br, —I, —CF 3 , —CN, N 3 , —NO 2 , or —OR 4 ; R 3b is ═O, —O(R 4 ), ═S, —N(R 4 ), —N(O)(R 4 ), —N(OR 4 ), —N(O)(OR 4 ), or —N(N(R 4 )(R 4 )); R 3c is —R 4 , —N(R 4 )(R 4 ), —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —S(O)(OR 4 ), —S(O) 2 (OR 4 ), —OC(R 3b )R 4 , —OC(R 3b )OR 4 , —OC(R 3b )(N(R 4 )(R 4 )), —SC(R 3b )R 4 , —SC(R 3b )OR 4 , —SC(R 3b )(N(R 4 )(R 4 )), —N(R 4 )C(R 3b )R 4 , —N(R 4 )C(R 3b )OR 4 , —N(R 4 )C(R 3b ) (N(R 4 )(R 4 )), W 3 or —R 5 W 3 ; R 3d is —C(R 3b )R 4 , —C(R 3b )OR 4 , —C(R 3b )W 3 , —C(R 3b )OW 3 or —C(R 3b )(N(R 4 )(R 4 )); R 4 is —H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R 5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W 3 is W 4 or W 5 ; W 4 is R 6 , —C(R 3b )R 6 , —C(R 3b )W 5 , —SO M2 R 6 , or —SO M2 W 5 , wherein R 6 is R 4 wherein each R 4 is substituted with 0 to 3 R 3 groups; W 5 is carbocycle or heterocycle wherein W 5 is independently substituted with 0 to 3 R 2 groups; and M2 is 0, 1 or 2; and pharmaceutically acceptable salts thereof.

  本发明涉及一种公式I的化合物和组合物，用作抗增殖剂，特别是抗HPV，其中：Y1A和Y1B独立地为Y1;RX1和RX2独立地为RX；Y1为═O，—O（RX），═S，—N（RX），—N（O）（RX），—N（ORX），—N（O）（ORX）或—N（N（RX）（RX））；RX独立地为R1，R2，R4，W3或保护基；R1独立地为—H或1至18个碳原子的烷基；R2独立地为R3或R4，其中每个R4独立地用0至3个R3基替代或在一个碳原子上结合，两个R2基形成3至8个碳原子的环，并且该环可以用0至3个R3基替代；R3为R3a，R3b，R3c或R3d，但当R3与杂原子结合时，则R3为R3c或R3d；R3a为—H，—F，—Cl，—Br，—I，—CF3，—CN，N3，—NO2或—OR4；R3b为═O，—O（R4），═S，—N（R4），—N（O）（R4），—N（OR4），—N（O）（OR4）或—N（N（R4）（R4））；R3c为—R4，—N（R4）（R4），—SR4，—S（O）R4，—S（O）2R4，—S（O）（OR4），—S（O）2（OR4），—OC（R3b）R4，—OC（R3b）OR4，—OC（R3b）（N（R4）（R4）），—SC（R3b）R4，—SC（R3b）OR4，—SC（R3b）（N（R4）（R4）），—N（R4）C（R3b）R4，—N（R4）C（R3b）OR4，—N（R4）C（R3b）（N（R4）（R4）），W3或—R5W3；R3d为—C（R3b）R4，—C（R3b）OR4，—C（R3b）W3，—C（R3b）OW3或—C（R3b）（N（R4）（R4））；R4为—H，或1至18个碳原子的烷基，2至18个碳原子的烯基或2至18个碳原子的炔基；R5为1至18个碳原子的亚烷基，2至18个碳原子的烯亚烷基或2至18个碳原子的炔亚烷基；W3为W4或W5；W4为R6，—C（R3b）R6，—C（R3b）W5，—SOM2R6或—SOM2W5，其中R6为R4，其中每个R4用0至3个R3基替代；W5为碳环或杂环，其中W5独立地用0至3个R2基替代；M2为0、1或2；以及其药学上可接受的盐。
• Nucleoside phosphonates and analogs thereof for the treatment of HPV-infections
  申请人：GILEAD SCIENCES, INC.

  公开号：EP2204374A1

  公开（公告）日：2010-07-07

  The invention relates to compounds of Formula IA and pharmaceutically acceptable salts thereof for use in the treatment of papilloma virus infections (HPV) wherein Y1A and Y1B are -NH(Rx) and Rx is as defined in the description.

  本发明涉及用于治疗乳头状瘤病毒感染（HPV）的式 IA 化合物及其药学上可接受的盐类。 其中 Y1A 和 Y1B 为-NH(Rx)，Rx 如描述中所定义。
• Synthesis of symmetrical pseudopeptides as potential inhibitors of the human immunodeficiency virus-1 protease
  作者：M Langlois、D Quintard、C Abalain

  DOI：10.1016/0223-5234(94)90025-6

  日期：1994.1

  It is demonstrated that HIV-1 protease is essential for the assembly and infectivity of the acquired immunodeficiency syndrome (AIDS) virus. This protease is an aspartyl protease with a 2-fold symmetry axis. Potential inhibitors were synthesized and consisted of a spacer linking 2 peptidic chains. They had to satisfy the following constraints: a C-2 symmetry axis, a backbone similar to the peptidic substrates, and side-chains filling the subsites S-n...S'(n). The compounds were synthesized via peptidic synthetic methods and evaluated in an enzymatic test with HIV-1 protease. Several compounds displayed an inhibitory activity at 10 mu M. They possessed the spacers CO, CO-CO, CO-CH2-CHOH-CO and the terminal chain Phe-O-iC(4)H(9). However, the structural-variation-based optimization of these different compounds failed and no potent inhibitors were prepared.